skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Dollar_pills

A US legislative provision endorsing the requirement that pharmaceutical manufacturers include the price of prescription drugs in direct-to-consumer advertising was removed from an appropriations bill that passed the Senate Sept. 18.

The provision was previously part of the Senate version of the legislation providing 2019 funding for the Defense Department and HHS but was not in the House version. The pricing transparency measure has been championed by Sens. Dick Durbin, D-Ill., and Chuck Grassley, R-Iowa. (Also see "HHS Rulemaking On Price Disclosures In DTC Ads Supported In Senate-Passed Bill" - Pink Sheet, 24 Aug, 2018.)

It is also among the proposals in the Trump Administration’s blueprint for lowering drug prices. Stakeholders are skeptical about whether such a requirement is legally feasible or would work. Nevertheless, HHS has forwarded a proposed rule on the measure to the Office of Management and Budget for review.

"It Is A Shame"

Grassley commented on the decision to strip the provision from the funding bill in a Sept. 13 statement. “It is a shame when Congress cannot pass a simple appropriations amendment to address high drug prices when that is the number one thing we are hearing from our constituents,” he said.

“If President Trump, AARP, Sen. Durbin, and I can agree on this policy, why is Congress allowing the drug companies to dictate policy?”

“All I’m asking is for transparency, and I’m disappointed this measure was pulled from the appropriations bill at the last minute,” Durbin added. “Democrats and Republicans agreed on this, and it’s so basic. I know ultimately we will find a way to prevail and put American consumers ahead of Big Pharma when it comes to this critical issue.”

The fact that the provision has been blocked in Congress does not mean the regulation will not move forward but it is a setback.

HHS Secretary Alex Azar has said it does not believe he needs legislation to authorize the DTC disclosure requirement. However, he has also said he would like congressional backing for the move, because it is  likely to be challenged in court.

Proposed Rule Would Be Implemented By CMS

HHS sent a proposed rule on enhancing drug price transparency to OMB for review on Aug. 23. The proposal would be implemented by the Centers for Medicare and Medicaid Services and focus on Medicare and Medicaid.

It’s unclear why the proposal is being issued under the auspices of CMS rather than FDA. It could be that HHS feels that implementation via CMS is the quickest route to take. FDA has said it is studying the issue.

The Coalition for Healthcare Communication believes the mandate would be bad public policy in the current pricing environment, Executive Director Jon Bigelow said in an interview. There is such wide variability in what patients pay that disclosure would produce confusion and could discourage some patients from seeking treatment, he explained.

Nevertheless, Bigelow (who just took over from long-time head John Kamp) predicted that the issue will surface again in Congress, given its support among Republicans, Democrats and the public. But it might not move until after the November elections, he suggested.

 

Read also

  • In Vivo: strategic insights for life sciences decision-maker...

    Pharma News and Healthcare Business Insights

    <p><span>Pharma Intelligence offers a wealth of pharmaceutical industry news and strategic insight into the healthcare &amp; biotechnology markets from around the world. Working in an interconnected global network, our 65 journalists and over 300 in-house analysts supply comprehensive analysis and reports.</span></p>

  • Pink Sheet: global policy and regulatory coverage

    Cancer Immunotherapy: When To Stop Treatment Remains Unanswered Question

    02 Aug 2017

    Long-term or open-ended treatment with PD-1/PD-L1 inhibitors is a burden for patients and the healthcare system and does not fit the biological paradigm of cancer immunotherapies, experts say; however, challenges to studying shorter durations include fears of undertreatment and patient objections to stopping a therapy that appears to be working.

    Topics Clinical trials

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: